Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia
Sign Up to like & getrecommendations! Published in 2022 at "Signal Transduction and Targeted Therapy"
DOI: 10.1038/s41392-021-00870-3
Abstract: Despite high initial response rates, acute myeloid leukemia (AML) treated with the BCL-2–selective inhibitor venetoclax (VEN) alone or in combinations commonly acquires resistance. We performed gene/protein expression, metabolomic and methylation analyses of isogenic AML cell… read more here.
Keywords: acute myeloid; activation; resistance; myeloid leukemia ... See more keywords
Abstract 2677: ROCK inhibitors synergize with the BCL2 inhibitor venetoclax for treatment of AML
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-2677
Abstract: Acute Myeloid Leukemia (AML) is a rare but catastrophic hematological cancer with a poor prognosis, high mortality, and relapse rates. Several new agents targeting specific genes or cell survival pathways have been recently approved by… read more here.
Keywords: rock; aml; rock inhibitors; treatment ... See more keywords
Rapid Complete Response to Single-Agent Bcl-2 Inhibitor Venetoclax in a Heart-Transplanted Patient with Triple Refractory Immunoglobulin Light-Chain Amyloidosis
Sign Up to like & getrecommendations! Published in 2020 at "Acta Haematologica"
DOI: 10.1159/000504355
Abstract: Immunoglobulin light-chain amyloidosis (AL) is a disease with limited treatment options due to the frailty of patients caused by organ damage. Since the clonal plasma cells often contain the cytogenetic aberration t(11;14), the Bcl-2 inhibitor… read more here.
Keywords: inhibitor venetoclax; chain amyloidosis; bcl inhibitor; immunoglobulin light ... See more keywords